Melatonin: Miracle Molecule or Misunderstood Supplement?

Introduction

Melatonin, a hormone central to regulating circadian rhythms and sleep, has evolved from a sleep aid into a proposed panacea for numerous conditions—from cancer and COVID-19 to aging and anxiety. But how much of this enthusiasm is scientifically justified?

This comprehensive critical review dissects decades of melatonin research, questioning exaggerated claims and evaluating the real evidence behind its physiological and clinical roles.

Key Takeaways at a Glance

• Melatonin regulates circadian rhythms and sleep through MT1 and MT2 receptors.
• Widespread clinical claims—ranging from antioxidant to anti-cancer effects—often lack robust evidence.
• Most effects at high doses are not receptor-mediated and are poorly understood mechanistically.
• Safety at high doses (up to 100 mg/day) is not well-established, especially in children and vulnerable populations.
• The antioxidant/scavenger role of melatonin is often overstated and misinterpreted in literature.
• Current trials span nearly all disease categories, but many are poorly designed or underpowered.

From Sleep Hormone to Universal Cure?

Originally discovered in 1958, melatonin’s primary physiological role is regulating the sleep-wake cycle. Its nighttime secretion by the pineal gland aligns the body's internal clock with environmental light.

In recent decades, however, melatonin has been tested or theorized as a treatment for hundreds of unrelated diseases. This explosion in speculative research has led to:

• Clinical trials in nearly every pathology, from Alzheimer’s and diabetes to viral infections and cancer
• Use of supra-physiological doses (often 10,000–100,000x endogenous levels)
• Poor understanding of mechanisms at high doses
• Misuse of preclinical findings and overgeneralized review articles

Clinical Trials: Quantity Over Quality?

• 742 clinical studies were found involving melatonin as of January 2023.
• Trials test melatonin across mental disorders, inflammation, pain, immune dysfunction, cardiovascular disease, and more.
• However, most are small-scale, use divergent dosing (0.5 mg to 100 mg/day), and lack long-term follow-up.
• Only a handful of cancer trials published results—most showing no significant benefit.
• Many trials still rely on non-pharmaceutical supplements, undermining reproducibility and dosage control.

Pediatric Use: A Cautionary Tale

While melatonin is commonly used in children with neurodevelopmental disorders like autism and ADHD, safety concerns remain:

• Over 250,000 pediatric ingestions were reported in the U.S. (2012–2021).
• At least 45,000 symptomatic cases and 2 deaths have been recorded.
• Use in infants and toddlers is especially concerning, with some reports linking melatonin ingestion to sudden unexplained deaths.

Despite widespread over-the-counter availability, no formal safety trials have assessed long-term effects in children.

Antioxidant or Overhyped Scavenger?

Melatonin is often labeled as a powerful antioxidant and ROS scavenger, yet:

• Its reaction rate with ROS is far lower than that of endogenous antioxidant enzymes like superoxide dismutase.
• Most experimental models use concentrations far beyond physiological relevance (often in millimolar ranges).
• Claims about melatonin's mitochondrial or bacterial origins and accumulation remain largely unproven or based on weak, unreproduced data.

The antioxidant narrative has been popularized, not necessarily validated.

Mechanistic Ambiguity: What Does Melatonin Actually Do?

Melatonin has been reported to:

• Inhibit hundreds of molecular pathways (Akt, mTOR, JNK, ERK, HIF-1α, NF-κB, etc.)
• Affect gene expression, apoptosis, autophagy, and mitochondrial health
• Exhibit contradictory actions depending on context and dose

However:

• Many studies lack dose-response curves or proper controls using structurally related indoles
• The “indole hypothesis” suggests that other indole compounds (e.g., serotonin, tryptamine) may have similar effects
• Most mechanistic claims are speculative, often conflating correlation with causation

Misinterpretations & Repetitive Review Cycles

A major concern is the uncritical propagation of hypotheses as facts:

• Withdrawn papers continue to be cited as proof (e.g., nuclear receptor RZRα).
• High-dose effects in preclinical models are generalized to human clinical use.
• Reviews copy and reinforce claims without fresh data, leading to confirmation bias in the literature.

Melatonin in the COVID-19 Era

Melatonin was proposed as a treatment for COVID-19 due to its:

• Antioxidant and anti-inflammatory effects
• Potential interference with ACE2 receptor binding

Yet:

• Most of the 200+ publications were theoretical reviews
• Actual experimental evidence is limited and contradictory
• In mouse models, melatonin protected the brain but not the lungs—with unclear relevance to human infection

Recommendations for Future Research

To restore scientific rigor in melatonin research:

• Avoid using non-physiological concentrations in models
• Include control compounds (e.g., N-acetylserotonin, tryptamine) to test specificity
• Determine EC50 values to assess molecular target engagement
• Conduct robust, long-term human safety trials, especially in children and vulnerable populations
• Distinguish between preventive and therapeutic paradigms

Conclusion

Melatonin remains a valuable tool for managing sleep disturbances and circadian rhythm disorders. However, its indiscriminate use as a “miracle molecule” is not supported by high-quality evidence. Most preclinical and clinical claims lack mechanistic clarity, dose relevance, or reproducibility.

Until these gaps are addressed, melatonin should be used with caution, especially in high doses and pediatric populations. The field must shift from overhyping speculative benefits to grounding its claims in rigorous experimental science.

Source:
Boutin, J. A., Kennaway, D. J., & Jockers, R. (2023). Melatonin: Facts, Extrapolations and Clinical Trials. PMC10295901 (https://pmc.ncbi.nlm.nih.gov/articles/PMC10295901/).